805250-20-8

Basic information

• Product Name: [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI)
• Synonyms: [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI)
• CAS NO: 805250-20-8
• Molecular Formula: C16H16O
• Molecular Weight: 224.3
• Product Categories: METHYL
• Mol File: 805250-20-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI)(805250-20-8)
• EPA Substance Registry System: [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI)(805250-20-8)

Safety Data

• Hazardous Substances Data: 805250-20-8(Hazardous Substances Data)

Usage

Description

[1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI) is a chemical compound with the molecular formula C18H16O. It is a derivative of biphenyl, a hydrocarbon consisting of two benzene rings linked together. This specific compound contains a carboxaldehyde group and three methyl groups attached to the biphenyl structure, making it a versatile building block in organic synthesis and a potential candidate for various applications in the pharmaceutical and materials science industries.

Uses

Used in Organic Synthesis:
[1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI) is used as a building block in organic synthesis for the production of various organic compounds and pharmaceuticals. Its unique structure with a carboxaldehyde group and three methyl groups allows for the creation of a wide range of molecules with diverse properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, [1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI) is used as a starting material for the synthesis of complex molecules with potential therapeutic properties. Its ability to be modified and functionalized makes it a valuable component in the development of new drugs and medications.
Used in Materials Science:
[1,1-Biphenyl]-3-carboxaldehyde,2,4,6-trimethyl-(9CI) also has potential applications in materials science, where it can be used to develop new materials with specific properties. Its structural characteristics may contribute to the creation of materials with enhanced performance in various applications, such as electronics, coatings, or adhesives.

Upstream product

• 73681-65-9 bis(2,4,6-trimethylphenyl)-zinc 
• 75148-49-1 3-bromobenzaldehyde diethylacetal 
• 576-83-0 2,4,6-trimethylphenyl bromide 
• 1256169-23-9 bis[3-(diethoxymethyl)phenyl]zinc 
• 3132-99-8 m-bromobenzoic aldehyde 
• 5980-97-2 mesitylboronic acid 

Downstream Products

• 805250-21-9 (2',4',6'-trimethylbiphenyl-3-yl)methanol 
• 805248-76-4 methyl 2-{6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetate 
• 805248-77-5 {6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 

Relevant articles and documents

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists

The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl} propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy} -2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.

3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES

The present invention provides a novel compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. They unexpectedly show superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful pharmaceutical agents for the prophylaxis or treatment of GPR40 receptor related diseases in mammals.